The Epstein Barr virus (EBV) is one of the predominant tumor viruses in humans, but so far no therapeutic or prophylactic vaccination against this transforming pathogen is available. We demonstrated that heterologous prime-boost vaccination with the nuclear antigen 1 of EBV (EBNA1) either targeted to the DEC205 receptor on dendritic cells or expressed from a recombinant modified vaccinia virus Ankara (MVA) vector improved priming of antigen-specific CD4 + T-cell help. This help supported the expansion and maintenance of EBNA1 specific CD8 + T cells that are most efficiently primed by recombinant adenoviruses that encode EBNA1. These combined CD4 + and CD8 + T-cell responses protected from EBNA1 expressing T and B cell lymphomas, including lymphoproliferations that emerge spontaneously after EBNA1 expression.
Abstract
The Epstein Barr virus (EBV) is one of the predominant tumor viruses in humans, but so far no therapeutic or prophylactic vaccination against this transforming pathogen is available. We demonstrated that heterologous prime-boost vaccination with the nuclear antigen 1 of EBV (EBNA1) either targeted to the DEC205 receptor on dendritic cells or expressed from a recombinant modified vaccinia virus Ankara (MVA) vector improved priming of antigen-specific
CD4
+ T-cell help. This help supported the expansion and maintenance of EBNA1 specific CD8 + T cells that are most efficiently primed by recombinant adenoviruses that encode EBNA1. These combined CD4 + and CD8 + T-cell responses protected from EBNA1 expressing T and B cell lymphomas, including lymphoproliferations that emerge spontaneously after EBNA1 expression.
In particular the heterologous EBNA1-expressing adenovirus, boosted by MVA vaccination, demonstrated protection as prophylactic and therapeutic treatment of the respective lymphoma challenges. Therefore, we suggest that such heterologous prime-boost vaccinations should be further explored for clinical development against EBV-associated malignancies as well as symptomatic primary EBV infection.
Introduction
Epstein-Barr virus (EBV) is one of the most successful human pathogens, establishing persistent infection in more than 95% of adults (1) . At the same time, this common -herpesvirus is also the most growth-transforming pathogen in vitro and associated with a variety of B-cell lymphomas and epithelial cell carcinomas in vivo (2) . These amount to around 200'000 new cancers every year, therefore EBV constitutes an important target for therapeutic intervention (3) . The viral tumorigenic potential is primarily due to the latent EBV infection programs, which express up to eight proteins and more than forty non-translated RNAs (1) . Together with these non-translated RNAs, the six nuclear antigens (EBNAs) and two latent membrane proteins Indeed the list of primary immunodeficiencies that predispose for EBV-associated diseases identifies cytotoxic lymphocytes as the cornerstone of this immune control (6, 8) . More specifically, mutations in T-cell receptor signaling identify conventional  T cells and innate NKT as well as  T cells as components of this immune control (9, 10) . Among these, conventional  T cells have been used therapeutically after expansion with LCLs or defined EBV antigens primarily for the treatment of PTLDs (11) . While the antigen specificities of these clinically efficacious T-cell transfers remain often undefined, EBNA1 has at least been identified as one of the protective EBV antigens by the treatment success after adoptive transfer of T-cell populations that have been selected via cytokine production in response to this latent EBV antigen (12) . Furthermore, EBNA1 is consistently recognized at least by CD4 + T cells in nearly all healthy EBV carriers (13, 14) , and both EBNA1-specific CD4 + and CD8 + T cells are able to target EBV-transformed B cells (15) (16) (17) In the first step towards the generation of EBNA1-Ab (antibody) fusion proteins the variable region sequences of the chosen antibodies were selected from mouse hybridoma cell lines. The sequenced variable regions of the heavy and light chains were synthesized into HEK expression vectors and the sequence coding for EBNA1 amino acids 400-641 was added to the heavy chain vector.
The EBNA1-Ab fusion proteins that were produced consisted of human constant regions including kappa light chain and IgG1 heavy chain, the EBNA1400-641 sequence and a His-tag for easier detection and purification ( Figure 1a ). The fusion antibodies only differ in their variable regions. EBNA1-Ab fusion proteins were produced in stable infected HEK293T cell lines and their purification was monitored by SDS-PAGE and EBNA1 Western blot, with which the heavy chain can be detected at an apparent weight of around 100kD (Figure 1b , Supplemental Figure   1b ). Binding specificity after cloning was confirmed through a competitive binding assay in which binding of the original hybridoma antibodies on a target cell could be overcome by prior incubation with the engineered antibody constructs (Supplemental Figure 1a) . EBNA1-Ab for all eight receptors and for DEC205 were produced and maintained their receptor binding activity.
To assess the MHC class I and II presentation of these receptor-targeted EBNA1-Abs, EBNA1-specific CD4 + and CD8 + T-cell clones were generated from healthy EBV carriers. CD4 + T-cell clones recognizing different epitopes, designated SNP restricted through HLA-DR51, NLR restricted through HLA-DR1 and AEG restricted through HLA-DQ2/3, were used. In addition, established EBNA1 specific CD8 + T-cell clones were used that were specific for the HPV epitope restricted through HLA-B35, because this specificity can be readily cloned from HLA- setting, mice were challenged on day 0 and immunization followed within one to seven days.
Tumor burden was analysed every second day by caliper measurement. In the challenge after prophylactic vaccination, in 11 out of 13 mice a complete EL4-E1 tumor rejection was seen in the case of αDEC-E1+Adeno-E1&LMP and Adeno-E1&LMP+MVA-IiE1 vaccination (Figure 4b ).
The survival rate of these mice was increased from 10 to 100% (Figure 4c 
Protection from EBNA1-induced B cell lymphoma challenge by heterologous vaccination
To test the most promising heterologous prime-boost vaccinations against a tumor model that more closely resembles human EBV-associated malignancies, especially c-myc driven Burkitt's lymphoma, we used an EBNA1-induced B cell lymphoma with C57BL/6 background (36). These Taken together, we conclude that αDEC-E1+Adeno-E1&LMP vaccination seems to lower the tumor burden upon BL-E1 injection, whereas Adeno-E1&LMP+MVA-IiE1 vaccination leads to a more effective reduction in tumor load, as indicated by the EBNA1 DNA load, spleen histology and EBNA1 specific Western blot analysis.
Characteristics of T-cell responses towards EBNA1-induced B cell lymphomas without and with protective vaccination
In order to investigate the different mechanisms of the vaccination strategies, used to restrict 
Viral Vectors
The Adeno-E1&LMP recombinant adenoviral vector used in this study carries an EBNA1-LMPpolyepitope insert, which is incorporated into the replication-deficient mammalian vector and were bred at 8-12 weeks of age at the local animal facility of the University of Zurich.
Maintenance of the huDEC205 transgene was controlled by PCR for each mouse using the by the TECAN microplate reader infinite M200 pro.
EBNA1 copy quantification by qPCR
DNA from single cell suspensions from blood, spleen, liver and LNs was isolated using DNA isolation kit (Qiagen). qPCR was performed using 25ng of each sample in triplicates with 
Histology
Tissue was fixed using 4% formalin and then embedded in paraffin. Histology stainings were performed by Sophistolab. For immunohistochemistry, 3 μm sections were processed on a Leica BOND-MAX or Bond-III automated immunohistochemistry system. Stainings were performed with monoclonal rat anti-mCD19 (clone 60MP31), rat anti-mCD4 (clone 4SM94), rat anti-mCD8(clone 4SM15), rat anti-FoxP3 (clone EP340) and anti-PCNA (clone PC10). EBNA1
specific immunohistochemistry was performed with the 1H4 antibody as previously described (63) .
In vivo immunization
Mice were injected intraperitoneally with 5 μg anti-mouse DEC205 fused with EBNA1 mAb with 50 μg poly(I:C)-LMW (polyIC) (Invivogen) as adjuvant (21) 
